

Darzalex Faspro® (daratumumab and hyaluronidase-fihi) – Expanded indication

- On July 12, 2021, <u>Janssen announced</u> the FDA approval of <u>Darzalex Faspro</u> (<u>daratumumab and hyaluronidase-fihj</u>), in combination with <u>Pomalyst®</u> (<u>pomalidomide</u>) and dexamethasone, for the treatment of adult patients with multiple myeloma in patients who have received at least one prior line of therapy including Revlimid® (lenalidomide) and a proteasome inhibitor.
- Darzalex Faspro is also approved for various other uses in multiple myeloma. Refer to the drug label for additional information.
- The approval of Darzalex Faspro for the expanded indication was based on APOLLO, an open label, randomized, active-controlled study in 304 patients with multiple myeloma. Patients received Darzalex Faspro plus Pomalyst and dexamethasone or Pomalyst and dexamethasone alone. The major efficacy outcome measure was progression-free survival (PFS).
 - The median PFS was 12.4 months in the Darzalex Faspro combination group vs. 6.9 months in the Pomalyst plus dexamethasone group (hazard ratio 0.63, 95% CI: 0.47, 0.85; p = 0.0018).
 - Overall response was 68.9% in the Darzalex Faspro combination group vs. 46.4% in the Pomalyst plus dexamethasone group (p < 0.0001).
- The recommended dose of Darzalex Faspro is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously over approximately 3 to 5 minutes. When used in combination with Pomalyst and dexamethasone, the recommend dosing schedule is weekly for weeks 1 to 8, every two weeks for weeks 9 to 24, and every four weeks for weeks 25 onwards until disease progression.
 - Darzalex Faspro should be administered by a healthcare provider.
 - Refer to the drug labels for Pomalyst and dexamethasone for their dosage recommendations.
 - Refer to the Darzalex Faspro drug label for dosing for all its other uses.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.